Ebstein畸形外科修复术中细胞输送:从安全性到获益的初步结果
本研究为开放标签、非随机I期临床试验,评估Ebstein畸形患者在三尖瓣修复术中经心肌注射自体骨髓单个核细胞(BM-MNC)的安全性和早期影响,目标剂量1-3百万细胞/kg。结论认为该操作安全,超声指标提示细胞治疗对右心室心肌有积极影响,但需额外随访和对照组比较。
要点
- Ebstein畸形修复术中经心肌注射BM-MNC未发生室性心律失常或相关不良事件。
- 6个月随访超声显示右心室心肌功能指数改善,面积变化分数先降后升。
- MRI未见注射部位延迟强化或局部室壁运动异常,提示安全性良好。
核心结论
- Ebstein畸形外科修复术中经心肌输送BM-MNC可安全实施。
- 超声心动图指标提示细胞输送对右心室心肌有积极影响,右心室大小和壁运动随时间改善。
- 需额外随访和对照组比较以更好表征细胞治疗对Ebstein畸形中病变右心室的影响。
研究设计与样本
- 开放标签、非随机I期临床试验。
- 纳入6个月至30岁、计划行三尖瓣修复的Ebstein畸形患者。
- BM-MNC目标剂量为1-3百万细胞/kg。
主要发现
- 所有患者均行外科三尖瓣修复,BM-MNC输送顺利。
- 无室性心律失常,无与研究产品及输送相关的不良事件。
- 超声心动图右心室心肌功能指数改善,右心室面积变化分数初始下降后在整个研究随访中上升。
- 6个月随访MRI未见延迟心肌强化或注射部位局部壁运动异常。
临床怎么用
- 对于接受外科修复的Ebstein畸形患者,术中经心肌注射BM-MNC在当前I期试验中显示安全性可控。
- 术后可通过超声心动图右心室心肌功能指数和面积变化分数动态评估右心室功能变化。
- 6个月MRI可用于排查注射部位延迟强化或局部壁运动异常。
局限性
- 开放标签、非随机设计,无对照组。
- 需额外随访和对照比较以进一步明确疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The objective of this study is to assess the safety and early impact of intramyocardial delivery of autologous bone marrow-derived mononuclear cells (BM-MNC) at time of surgical Ebstein repair. METHODS: Patients with Ebstein anomaly (ages 6 months to 30 years) scheduled to undergo repair of the tricuspid valve were eligible to participate in this open-label, non-randomized phase I clinical trial. BM-MNC target dose was 1-3 million cells/kg. Ten patients have undergone surgical intervention and cell delivery to the right ventricle (RV) and completed 6-month follow-up. RESULTS: All patients underwent surgical tricuspid valve repair and uneventful BM-MNC delivery; there were no ventricular arrhythmias and no adverse events related to study product or delivery. Echocardiographic RV myocardial performance index improved and RV fractional area change showed an initial decline and then through study follow-up. There was no evidence of delayed myocardial enhancement or regional wall motion abnormalities at injection sites on 6-month follow-up magnetic resonance imaging. CONCLUSIONS: Intramyocardial delivery of BM-MNC after surgical repair in Ebstein anomaly can be performed safely. Echocardiography variables suggest a positive impact of cell delivery on the RV myocardium with improvements in both RV size and wall motion over time. Additional follow-up and comparison to control groups are required to better characterize the impact of cell therapy on the myopathic RV in Ebstein anomaly.
引用
- Holst KA, Dearani JA, Qureshi MY, et al. From Safety to Benefit in Cell Delivery During Surgical Repair of Ebstein Anomaly: Initial Results. Ann Thorac Surg. 2021. PMID: 33539782. doi:10.1016/j.athoracsur.2020.11.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。